Close Menu

NEW YORK – A multiplex molecular panel to detect pneumonia-causing pathogens has been shown to potentially benefit patient care, according to a handful of recent studies. In one study, the test, from BioMérieux subsidiary BioFire Diagnostics, was shown to have the potential to adjust antimicrobial therapy in approximately 70 percent of cases, sparing patients six days of unnecessary empiric treatment.

Additionally, the panel is finding a place in the COVID-19 diagnostic testing workflow in the UK.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Sponsored by

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints.